LymphedemaV1, Ncbi, Checkpoint, bibRecord, 003B66

Angiosarcoma.

Identifieur interne : 003B66 ( Ncbi/Checkpoint ); précédent : 003B65; suivant : 003B67

Angiosarcoma.

Auteurs : Robin J. Young [Royaume-Uni] ; Nicola J. Brown ; Malcolm W. Reed ; David Hughes ; Penella J. Woll

Source :

The Lancet. Oncology [ 1474-5488 ] ; 2010.

RBID : pubmed:20537949

Descripteurs français

KwdFr :
- Diagnostic différentiel, Facteurs de risque, Femelle, Humains, Hémangiosarcome (), Hémangiosarcome (anatomopathologie), Hémangiosarcome (diagnostic), Hémangiosarcome (génétique), Hémangiosarcome (étiologie), Mâle, Résultat thérapeutique, Stade de la tumeur, Valeur prédictive des tests.
MESH :
- anatomopathologie : Hémangiosarcome.
- diagnostic : Hémangiosarcome.
- génétique : Hémangiosarcome.
- étiologie : Hémangiosarcome.
- Diagnostic différentiel, Facteurs de risque, Femelle, Humains, Hémangiosarcome, Mâle, Résultat thérapeutique, Stade de la tumeur, Valeur prédictive des tests.

English descriptors

KwdEn :
- Diagnosis, Differential, Female, Hemangiosarcoma (diagnosis), Hemangiosarcoma (etiology), Hemangiosarcoma (genetics), Hemangiosarcoma (pathology), Hemangiosarcoma (therapy), Humans, Male, Neoplasm Staging, Predictive Value of Tests, Risk Factors, Treatment Outcome.
MESH :
- diagnosis : Hemangiosarcoma.
- etiology : Hemangiosarcoma.
- genetics : Hemangiosarcoma.
- pathology : Hemangiosarcoma.
- therapy : Hemangiosarcoma.
- Diagnosis, Differential, Female, Humans, Male, Neoplasm Staging, Predictive Value of Tests, Risk Factors, Treatment Outcome.

Abstract

Angiosarcomas are rare soft-tissue sarcomas of endothelial cell origin that have a poor prognosis. They can arise anywhere in the body, most commonly presenting as cutaneous disease in elderly white men, involving the head and neck and particularly the scalp. They can be caused by therapeutic radiation or chronic lymphoedema and hence secondary breast angiosarcomas are an important subgroup. Recent work has sought to establish the molecular biology of angiosarcomas and identify specific targets for treatment. Interest is now focused on trials of vascular-targeted drugs, which are showing promise in the control of angiosarcomas. In this review we discuss angiosarcoma and its current management, with a focus on clinical trials investigating the treatment of advanced disease.

DOI: 10.1016/S1470-2045(10)70023-1
PubMed: 20537949

Affiliations:

Royaume-Uni

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 002A41
to stream PubMed, to step Curation: 002A41
to stream PubMed, to step Checkpoint: 002A41
to stream Ncbi, to step Merge: 003B66
to stream Ncbi, to step Curation: 003B66

Links to Exploration step

pubmed:20537949

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Angiosarcoma.</title>
<author><name sortKey="Young, Robin J" sort="Young, Robin J" uniqKey="Young R" first="Robin J" last="Young">Robin J. Young</name>
<affiliation wicri:level="1"><nlm:affiliation>Academic Unit of Surgical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK. r.j.young@shefeld.ac.uk</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Academic Unit of Surgical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield</wicri:regionArea>
<wicri:noRegion>Sheffield</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brown, Nicola J" sort="Brown, Nicola J" uniqKey="Brown N" first="Nicola J" last="Brown">Nicola J. Brown</name>
</author>
<author><name sortKey="Reed, Malcolm W" sort="Reed, Malcolm W" uniqKey="Reed M" first="Malcolm W" last="Reed">Malcolm W. Reed</name>
</author>
<author><name sortKey="Hughes, David" sort="Hughes, David" uniqKey="Hughes D" first="David" last="Hughes">David Hughes</name>
</author>
<author><name sortKey="Woll, Penella J" sort="Woll, Penella J" uniqKey="Woll P" first="Penella J" last="Woll">Penella J. Woll</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="RBID">pubmed:20537949</idno>
<idno type="pmid">20537949</idno>
<idno type="doi">10.1016/S1470-2045(10)70023-1</idno>
<idno type="wicri:Area/PubMed/Corpus">002A41</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002A41</idno>
<idno type="wicri:Area/PubMed/Curation">002A41</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002A41</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002A41</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002A41</idno>
<idno type="wicri:Area/Ncbi/Merge">003B66</idno>
<idno type="wicri:Area/Ncbi/Curation">003B66</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003B66</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Angiosarcoma.</title>
<author><name sortKey="Young, Robin J" sort="Young, Robin J" uniqKey="Young R" first="Robin J" last="Young">Robin J. Young</name>
<affiliation wicri:level="1"><nlm:affiliation>Academic Unit of Surgical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK. r.j.young@shefeld.ac.uk</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Academic Unit of Surgical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield</wicri:regionArea>
<wicri:noRegion>Sheffield</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brown, Nicola J" sort="Brown, Nicola J" uniqKey="Brown N" first="Nicola J" last="Brown">Nicola J. Brown</name>
</author>
<author><name sortKey="Reed, Malcolm W" sort="Reed, Malcolm W" uniqKey="Reed M" first="Malcolm W" last="Reed">Malcolm W. Reed</name>
</author>
<author><name sortKey="Hughes, David" sort="Hughes, David" uniqKey="Hughes D" first="David" last="Hughes">David Hughes</name>
</author>
<author><name sortKey="Woll, Penella J" sort="Woll, Penella J" uniqKey="Woll P" first="Penella J" last="Woll">Penella J. Woll</name>
</author>
</analytic>
<series><title level="j">The Lancet. Oncology</title>
<idno type="eISSN">1474-5488</idno>
<imprint><date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Diagnosis, Differential</term>
<term>Female</term>
<term>Hemangiosarcoma (diagnosis)</term>
<term>Hemangiosarcoma (etiology)</term>
<term>Hemangiosarcoma (genetics)</term>
<term>Hemangiosarcoma (pathology)</term>
<term>Hemangiosarcoma (therapy)</term>
<term>Humans</term>
<term>Male</term>
<term>Neoplasm Staging</term>
<term>Predictive Value of Tests</term>
<term>Risk Factors</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Diagnostic différentiel</term>
<term>Facteurs de risque</term>
<term>Femelle</term>
<term>Humains</term>
<term>Hémangiosarcome ()</term>
<term>Hémangiosarcome (anatomopathologie)</term>
<term>Hémangiosarcome (diagnostic)</term>
<term>Hémangiosarcome (génétique)</term>
<term>Hémangiosarcome (étiologie)</term>
<term>Mâle</term>
<term>Résultat thérapeutique</term>
<term>Stade de la tumeur</term>
<term>Valeur prédictive des tests</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Hémangiosarcome</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Hemangiosarcoma</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Hémangiosarcome</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Hemangiosarcoma</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Hemangiosarcoma</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Hémangiosarcome</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Hemangiosarcoma</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Hemangiosarcoma</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Hémangiosarcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Diagnosis, Differential</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Neoplasm Staging</term>
<term>Predictive Value of Tests</term>
<term>Risk Factors</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Diagnostic différentiel</term>
<term>Facteurs de risque</term>
<term>Femelle</term>
<term>Humains</term>
<term>Hémangiosarcome</term>
<term>Mâle</term>
<term>Résultat thérapeutique</term>
<term>Stade de la tumeur</term>
<term>Valeur prédictive des tests</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Angiosarcomas are rare soft-tissue sarcomas of endothelial cell origin that have a poor prognosis. They can arise anywhere in the body, most commonly presenting as cutaneous disease in elderly white men, involving the head and neck and particularly the scalp. They can be caused by therapeutic radiation or chronic lymphoedema and hence secondary breast angiosarcomas are an important subgroup. Recent work has sought to establish the molecular biology of angiosarcomas and identify specific targets for treatment. Interest is now focused on trials of vascular-targeted drugs, which are showing promise in the control of angiosarcomas. In this review we discuss angiosarcoma and its current management, with a focus on clinical trials investigating the treatment of advanced disease.</div>
</front>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
</list>
<tree><noCountry><name sortKey="Brown, Nicola J" sort="Brown, Nicola J" uniqKey="Brown N" first="Nicola J" last="Brown">Nicola J. Brown</name>
<name sortKey="Hughes, David" sort="Hughes, David" uniqKey="Hughes D" first="David" last="Hughes">David Hughes</name>
<name sortKey="Reed, Malcolm W" sort="Reed, Malcolm W" uniqKey="Reed M" first="Malcolm W" last="Reed">Malcolm W. Reed</name>
<name sortKey="Woll, Penella J" sort="Woll, Penella J" uniqKey="Woll P" first="Penella J" last="Woll">Penella J. Woll</name>
</noCountry>
<country name="Royaume-Uni"><noRegion><name sortKey="Young, Robin J" sort="Young, Robin J" uniqKey="Young R" first="Robin J" last="Young">Robin J. Young</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B66 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 003B66 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Ncbi
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:20537949
   |texte=   Angiosarcoma.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i   -Sk "pubmed:20537949" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Angiosarcoma.

Angiosarcoma.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki